Direxion Daily S&P Biotech Bear 3X ETF (LABD)
24.87
-0.09 -0.36%
NYSE Arca
Sep 19, 20:00
Delayed 2m
USD
LABD Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
| 1 Year Fund Level Flows | Upgrade |
View All LABD News
LABD News
-
WireHeadlineTime (ET)
-
SA Breaking News06/22 12:07
-
SA Breaking News03/05 11:09
-
PR Newswire02/28 16:30
-
SA Breaking News12/29 08:03
-
SA Breaking News10/30 14:34
-
SA Breaking News07/06 15:09
-
SA Breaking News06/26 04:46
-
SA Breaking News06/21 19:22
-
SA Breaking News06/07 14:02
-
SA Breaking News03/24 16:02
LABD Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | -5.38% | -5.49% | -- | -- |
| 3M | 1.49% | 1.57% | -- | -- |
| 6M | -19.03% | -19.03% | -- | -- |
| YTD | -45.73% | -45.84% | -- | -- |
| 1Y | -50.36% | -50.36% | -- | -- |
| 3Y | -56.40% | -56.36% | -- | -- |
| 5Y | -- | -- | -- | -- |
| 10Y | -- | -- | -- | -- |
LABD Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 114.7% | 114.7% | 0.00% |
| Stock | -14.68% | 0.00% | 14.68% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
LABD Region Exposure
| Americas | 100.0% |
| North America | 100.0% |
| Latin America | 0.00% |
| Greater Europe | 0.00% |
| United Kingdom | 0.00% |
| Europe Developed | 0.00% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.00% |
| Greater Asia | 0.00% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.00% |
| Asia Emerging | 0.00% |
| Market Classification | |
| % Developed Markets | 100.0% |
| % Emerging Markets | 0.00% |
LABD Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.00% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 0.00% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.00% |
| Utilities | 0.00% |
LABD Stock Market Capitalization
| Giant | -- |
| Large | -- |
| Medium | -- |
| Small | -- |
| Micro | -- |
LABD Stock Style Exposure
| Large Cap Value | -- |
| Large Cap Blend | -- |
| Large Cap Growth | -- |
| Mid Cap Value | -- |
| Mid Cap Blend | -- |
| Mid Cap Growth | -- |
| Small Cap Value | -- |
| Small Cap Blend | -- |
| Small Cap Growth | -- |
View More Holdings
As of Aug. 31, 2018
LABD Top 1 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| -- | S&P Biotechnology Select | -14.68% | -- | -- |
Advertisement
LABD One Page Reports
- One Page Report Download
LABD Basic Info
| Style | |
|---|---|
| Broad Asset Class | Alternative |
| Broad Category | Alternative |
| Category Name | Trading--Inverse Equity |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Direxion Funds |
| Benchmark Index | |
|---|---|
S&P Biotechnology Select Industry TR USD |
-300.0% |
LABD Manager Info
| Name | Tenure |
|---|---|
| Paul Brigandi | 3.18 yrs |
| Tony Ng | 2.84 yrs |
LABD Net Fund Flows
| 1M | 21.64M |
| 3M | 2.310M |
| 6M | 23.63M |
| YTD | 31.95M |
| 1Y | 25.23M |
| 3Y | 201.60M |
| 5Y | -- |
| 10Y | -- |
LABD Risk Info
| Beta (5Y) | -6.364 |
| Max Drawdown (All) | 97.67% |
| Historical Sharpe (10Y) | -- |
| Historical Sortino (All) | -0.9131 |
| 30-Day Rolling Volatility | 48.82% |
| Daily Value at Risk (VaR) 1% (All) | 14.29% |
| Monthly Value at Risk (VaR) 1% (All) | 41.54% |
LABD Fundamentals
| Dividend Yield TTM (9-19-18) | 0% |
| SEC Yield | -- |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Forecasted Dividend Yield | -- |
| Forecasted PE Ratio | -- |
| Forecasted Price to Sales Ratio | -- |
| Forecasted Price to Book Ratio | -- |
| Number of Holdings | 9 |
LABD Growth Estimates
| Forecasted 5 Yr Earnings Growth | -- |
| Forecasted Book Value Growth | -- |
| Forecasted Cash Flow Growth | -- |
| Forecasted Earnings Growth | -- |
| Forecasted Revenue Growth | -- |
LABD Attributes
| Key Dates | |
|---|---|
| Inception Date | 5/28/2015 |
| Termination Date | |
| Last Annual Report Date | 10/31/2017 |
| Last Prospectus Date | 2/28/2018 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | Yes |
| Leveraged Fund | Yes |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
LABD Excel Add-In Codes
- Name: =YCI("LABD","name")
- Broad Asset Class: =YCI("LABD", "broad_asset_class")
- Broad Category: =YCI("LABD", "broad_category_group")
- Prospectus Objective: =YCI("LABD", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
